Clinical studies in patients with relapsing remitting-MS (RR-MS) confirmed an association between higher levels of IL-6 in the cerebrospinal fluid (CSF) and a worse disease course characterized by an increased relapse rate and greater disability [6,7]. Here, IL6 is linked to myeloid sarcoma.